A roundtable discussion, moderated by Thomas Martin, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, focused on CAR T-cell therapy considerations in the treatment of multiple myeloma, including data on approved CAR-T options and a look at the pipeline. Dr. Martin was joined by a panel that included Sagar Lonial, MD, FACP; Peter Voorhees, MD; and Shambavi Richard, MD.

In the next segment of the roundtable series, the panel debates whether CAR-T can be moved earlier in the course of myeloma treatment, including a discussion on the KarMMa-2 and KarMMa-3 trials assessing idecabtagene vicleucel in different clinical scenarios and the CARTITUDE-2 cohorts receiving ciltacabtagene autoleucel.

свернуть